Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Rab Diagnostics has developed a proprietary diagnostic platform leveraging the quantification of RabGTPase proteins—especially Rab5—as predictive biomarkers for patient stratification and response prediction to Antibody Drug Conjugate therapies in oncology. Their technology has been validated across multiple ADCs and cancer types, with verification in three independent clinical cohorts. The company’s first commercial product targets breast cancer patients eligible for T-DM1 therapy. They have received the European Innovation Council's "Seal of Excellence" and are preparing for rapid commercialization.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Rab Diagnostics.